The 36-month beta value for CARA is at 0.66. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for CARA is 45.76M, and currently, shorts hold a 2.06% of that float. The average trading volume for CARA on November 15, 2024 was 487.70K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CARA) stock’s latest price update
Cara Therapeutics Inc (NASDAQ: CARA)’s stock price has plunge by -6.17relation to previous closing price of 0.33. Nevertheless, the company has seen a -9.56% plunge in its stock price over the last five trading sessions. benzinga.com reported 2024-06-13 that Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
CARA’s Market Performance
Cara Therapeutics Inc (CARA) has seen a -9.56% fall in stock performance for the week, with a 15.22% gain in the past month and a -5.04% plunge in the past quarter. The volatility ratio for the week is 8.64%, and the volatility levels for the past 30 days are at 8.72% for CARA. The simple moving average for the past 20 days is 2.87% for CARA’s stock, with a -40.37% simple moving average for the past 200 days.
Analysts’ Opinion of CARA
Many brokerage firms have already submitted their reports for CARA stocks, with Stifel repeating the rating for CARA by listing it as a “Hold.” The predicted price for CARA in the upcoming period, according to Stifel is $1 based on the research report published on June 13, 2024 of the current year 2024.
CARA Trading at 7.43% from the 50-Day Moving Average
After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.53% of loss for the given period.
Volatility was left at 8.72%, however, over the last 30 days, the volatility rate increased by 8.64%, as shares surge +19.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.80% lower at present.
During the last 5 trading sessions, CARA fell by -6.94%, which changed the moving average for the period of 200-days by -43.61% in comparison to the 20-day moving average, which settled at $0.2995. In addition, Cara Therapeutics Inc saw -58.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CARA starting from Posner Christopher, who sale 3,668 shares at the price of $0.29 back on Nov 04 ’24. After this action, Posner Christopher now owns 168,768 shares of Cara Therapeutics Inc, valued at $1,064 using the latest closing price.
Posner Christopher, the PRESIDENT AND CEO of Cara Therapeutics Inc, sale 4,149 shares at $0.35 during a trade that took place back on Aug 01 ’24, which means that Posner Christopher is holding 172,436 shares at $1,452 based on the most recent closing price.
Stock Fundamentals for CARA
Current profitability levels for the company are sitting at:
- -9.47 for the present operating margin
- 0.74 for the gross margin
The net margin for Cara Therapeutics Inc stands at -10.1. The total capital return value is set at -1.78. Equity return is now at value -184.32, with -107.38 for asset returns.
Based on Cara Therapeutics Inc (CARA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -475.62. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -23.16.
Currently, EBITDA for the company is -117.65 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of -2.26. The receivables turnover for the company is 6.04for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
In conclusion, Cara Therapeutics Inc (CARA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
